Alto Neuroscience (ANRO) Corporate presentation summary

Mission and strategic approach

• Aims to redefine psychiatry by developing personalized, neurobiology-driven medicines for mental health disorders.

• Focuses on precision medicine using biomarkers to identify responsive patient populations and guide drug development.

• Addresses unmet needs in mental health, targeting conditions like depression and schizophrenia, which are leading causes of disability.

Clinical pipeline and programs

• Robust late-stage pipeline includes ALTO-207 for treatment-resistant depression (TRD), ALTO-300 for major depressive disorder (MDD), and ALTO-100 for bipolar depression.

• ALTO-207 combines a dopamine D3/D2 agonist with a 5-HT3 antagonist to enhance efficacy and tolerability in TRD.

• ALTO-300 leverages agomelatine’s multi-modal action and is guided by EEG biomarkers for adjunctive MDD treatment.

• ALTO-100 targets hippocampal neuroplasticity deficits in bipolar depression, using cognitive biomarkers for patient selection.

• Additional programs include ALTO-101 (PDE4 inhibitor for cognitive disorders) and ALTO-203 (H3 inverse agonist for neuropsychiatric disorders).

Key clinical data and differentiation

• ALTO-207 enables higher, faster pramipexole dosing with improved tolerability, showing significant antidepressant effects in Phase 2a.

• Pramipexole demonstrates robust efficacy and strong effects on anhedonia, with a favorable safety profile in TRD.

• ALTO-300 shows superior efficacy and tolerability versus SSRIs/SNRIs, with low risk of liver function test (LFT) elevation at 25mg.

• Biomarker-guided trials for ALTO-300 and ALTO-100 prospectively identify likely responders, improving trial outcomes and patient benefit.